Introduction
============

Endometrial cancer is the most common gynaecological malignancy in women from developed countries ([@bib1]), and breast cancer is the most common cancer that develops in women worldwide and is responsible for the most female cancer deaths ([@bib2]). The incidence of both of these hormone-related cancers has been steadily increasing in Australia and other Western and developing countries over the past 20 years ([@bib3], [@bib4], [@bib5]).

Oestrogen exposure is a major risk factor for these cancers ([@bib6]), with other risk factors including obesity and lack of physical activity ([@bib7], [@bib8], [@bib9]). Body mass index (BMI) is generally used as an indirect measure of an individual's weight or adiposity ([@bib10], [@bib11], [@bib12]). An increased BMI is proving to be a major risk factor for cancer ([@bib13], [@bib14]), and increased rates of hormone-related cancer types in particular appear to be associated with increases in obesity ([@bib5]). An increase in weight and hence adipose tissue leads to altered cytokine and hormone levels, including increased circulating oestrogen ([@bib8], [@bib11], [@bib12]). The increase in oestrogen is thought to alter the risk of malignancy via its effects on cellular proliferation, differentiation and apoptosis ([@bib7]).

Insulin-like growth factor I (IGF1) is a peptide hormone with important regulatory roles in cell growth, differentiation and apoptosis ([@bib15], [@bib16]), and is also required for normal breast development ([@bib17]). Epidemiological studies have shown that high circulating levels of IGF1 are associated with an increased risk of developing breast cancer, as well as prostate, colorectal and lung cancers ([@bib15], [@bib18], [@bib19], [@bib20]). Also, mammographic density, which is a strong predictor of breast cancer risk, has been correlated with plasma IGF1 levels in premenopausal women ([@bib21]). Hence, polymorphisms in the *IGF1* gene have been extensively analysed in relation to breast cancer risk, although the results have been variable and sometimes contradictory ([@bib19], [@bib22], [@bib23], [@bib24], [@bib25]), most likely due to differences in ethnic composition of the populations studied ([@bib26]).

The human *IGF1* gene (located at 12q23.2) is under the control of two promoters, one of which (P1) contains a polymorphic short tandem repeat (STR), being a dinucleotide cytosine--adenine (CA) repeat ([@bib27], [@bib28], [@bib29]). The number of CA repeats ranges from 10 to 25, with the most common allele in Caucasian populations being 19 repeats ([@bib30]). It was found that the CA repeat length was related to serum IGF1 levels ([@bib31]). Hence, this polymorphism has been predicted to affect transcription rates of *IGF1* ([@bib31]) because it is within 1 kb of the transcription start site and is known to contain regulatory elements ([@bib32]), in much the same way as the polymorphic CA repeat in the regulatory region of the epidermal growth factor receptor gene (*EGFR*) has been shown to influence transcription of *EGFR* ([@bib33]). This latter polymorphism has also been associated with the risk of developing breast cancer ([@bib34]) and lung cancer ([@bib35]). It has hence been postulated that the polymorphic CA repeat in the *IGF1* promoter may influence circulating IGF1 levels and thus be associated with cancer risk ([@bib18]).

The polymorphic STR in the *IGF1* promoter has been shown, from analysis in our laboratory and by others, to be associated with earlier age at onset of hereditary non-polyposis colorectal cancer ([@bib36], [@bib37], [@bib38]). Results of early studies also suggested an association between the absence of the common *IGF1* 19 CA repeat allele and increased breast cancer risk ([@bib26], [@bib39]). However, recent reports, including several meta-analyses, have found no association between the length of this CA repeat and the risk of developing breast cancer ([@bib18], [@bib22], [@bib40]). In cervical cancer, a recent study found significant differences in the repeat length between some types of cervical cancer and control groups ([@bib41]), whereas no association was found with cervical cancer risk in an earlier study ([@bib42]). These discrepancies may result from ethnic differences between cohorts and some studies having limited power due to small sample sizes.

To our knowledge, the CA repeat polymorphism in the *IGF1* promoter has not been analysed in relation to the risk of developing endometrial cancer. This study was undertaken, using a case--control design, to determine whether changes in the CA repeat length were associated with the risk of developing the oestrogen-driven malignancies, breast cancer or endometrial cancer.

Materials and methods
=====================

Patient and control samples
---------------------------

This study included 223 breast cancer cases, 204 endometrial cancer cases and 220 healthy controls from whom blood samples were taken and genomic DNA extracted using the salt extraction method ([@bib43]). The breast cancer patients were sourced from the Hunter Area Pathology Service as described previously ([@bib44]). They were all female, with early-onset (\<40 years) or bilateral breast cancer, with no known breast cancer predisposition genetic mutations. The DNA from the endometrial cancer cases was collected for previous studies from patients who had presented at the Hunter Centre for Gynaecological Cancer, John Hunter Hospital, Newcastle, NSW, Australia between the years 1992 and 2005 ([@bib45]). Healthy controls were selected from the Hunter Community Study (HCS) cohort ([@bib46]), with the requirement that individuals were female and had no history of cancer. The HCS participants were 55--85 years old, randomly recruited from the electoral roll between the years 2004 and 2005 from the Hunter region, Newcastle, NSW, Australia. All participants provided written informed consent for the DNA samples to be used for research. Ethics approval was obtained from the Human Research Ethics Committee, University of Newcastle, and the Hunter New England Human Research Ethics Committee, Hunter New England Health Service, Newcastle, NSW, Australia.

Genotyping the CA repeat
------------------------

The CA repeat, situated 788 base pairs (bp) upstream of the transcription start site for *IGF1*, was genotyped by polymerase chain reaction (PCR) and fragment analysis using forward (5′-gctagccagctggtgttatt-3′) and reverse (5′-accactctgggagaagggta-3′) primers designed to amplify a 194-bp length fragment as described previously ([@bib29]). PCR was performed in 10μL reactions using 40ng genomic DNA, 1× Platinum *Taq* High Fidelity buffer (Invitrogen), 0.2mM dNTPs, 1.0mM MgSO~4~, 0.4mM forward primer labelled with 6-carboxyfluorescein (6-FAM), 0.4mM reverse primer and 0.5U of Platinum *Taq* DNA Polymerase High Fidelity (Invitrogen). PCRs were performed in a GeneAmp PCR System 9700 (Applied Biosystems) using the following cycles: 94°C for 2min, followed by 35 cycles of 94°C for 30s, 60°C for 30s, 72°C for 1min, and then 72°C for 5min. Amplified DNA products were used neat or diluted 1:10 or 1:100 in Hi-Di Formamide (Applied Biosystems) dependent upon optimisation results, and denatured for 3min at 95°C, with the addition of Hi-Di Formamide and 0.5μL GeneScan 600 LIZ Size Standard (Applied Biosystems). The denatured product was then size separated by capillary electrophoresis on an ABI 3730 DNA Analyzer (Applied Biosystems). The results were analysed using Peak Scanner v1.0 software (Applied Biosystems).

Sanger sequencing was used to confirm the STR length in at least 10% of the samples and to demonstrate that differences in amplified product sizes were due to the length of the STR and not to other sequence changes. PCRs were performed as described previously, but with standard forward and reverse primers (no FAM label). They were treated with ExoSAP mix (exonuclease I and shrimp alkaline phosphatase; Thermo Fisher Scientific) before being bidirectionally sequenced with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). The sequencing products were cleaned up using Agencourt CleanSEQ (Beckman Coulter) and then size separated by capillary electrophoresis on an ABI 3730 DNA Analyzer (Applied Biosystems). The sequencing traces were analysed using Mutation Surveyor v3.97 software (SoftGenetics, State College, PA, USA). A line of best fit was formed from the direct sequencing results to correct the lengths obtained from fragment analysis as described by Pasqualotto and coworkers ([@bib47]).

Statistical analysis
--------------------

Statistical analyses were performed using the Stata 11.1 software package (StataCorp LP, College Station, TX, USA). The *t*-tests were used to test case--control differences in continuous STR length when STR length was normally distributed. The non-parametric equivalent (Mann--Whitney rank-sum/*U* test) was used for analysing STR lengths when deviation from a normal distribution was observed. Cox proportional hazard regression analysis was used to assess association between STR length and age at diagnosis. A Pearson *χ*^2^ test was used to analyse STR length when it was treated as a categorical variable, being divided into three groups: STR length equal to 19 (being 19 CA repeats, the most common allele length; CA=19), CA length less than 19 (CA\<19) and CA length greater than 19 (CA \> 19), as is most commonly done when analysing this particular STR ([@bib18], [@bib41]). The significance levels of all tests were set at a *P* value \<0.05 (two-sided) and then corrected for multiple comparisons using the Bonferroni method.

The hypotheses we set out to test were that an altered length of the *IGF1* STR would be associated with the risk of breast or endometrial cancer and/or the age at diagnosis of breast or endometrial cancer. We considered STR length as a continuous variable (for both alleles and separately by long and short allele) as well as a categorical variable (CA\<19, CA=19 and CA \> 19). According to the Bonferroni method, when we consider our original two outcomes (being occurrence of cancer and age at diagnosis) and three predictors (both short and long alleles or categories; 2×3=6 tests), our adjusted significance threshold is *α*=0.05/6=0.008. We have adjusted for three predictors as the categories are not independent predictors.

Results
=======

The demographic and clinical characteristics of the participants used in this study are shown in [Table 1](#tbl1){ref-type="table"}. The majority of individuals in these cohorts had Caucasian ethnicity; ethnicity details were not available for the breast cancer cohort. The non-Caucasian samples and those with missing ethnicity (contributing 3.4% of the endometrial cancer cohort and 5.5% of the healthy controls) are described in [Table 1](#tbl1){ref-type="table"}. Table 1Demographic and clinical characteristics of the participants in this study.**CharacteristicBreast cancer** (*n* = 223)**Endometrial cancer** (*n* = 204)**Healthy controls** (*n* = 220)SexAll femaleAll femaleAll femaleAge (at ascertainment; in years) RangeNA40--9267--86 Median6873 Mean ([s.d.]{.smallcaps})67.9 (9.5)73.4 (4.6)Age (at diagnosis; in years) Range22--5737--86NA Median4163.5 Mean ([s.d.]{.smallcaps})39.8 (7.3)63.2 (9.0)BMI (in kg/m^2^) RangeNA16.9--66.617.4--47.1 Median30.027.9 Mean ([s.d.]{.smallcaps})31.3 (7.8)28.5 (5.3) Underweight (BMI\<18.5)*n*=1*n*=1 Normal (18.5 ≤ BMI\<25)*n*=37*n*=58 Overweight (25 ≤ BMI\<30)*n*=56*n*=91 Obese (BMI≥30)*n*=94*n*=70 Not specified*n*=16*n*=0Type of endometrial cancer Type I (endometrioid adenocarcinoma, squamous)NA144 (70.6%)NA Type II (clear cell, UPSC, sarcomas, mucinous, MMMT)23 (11.3%) Other (leiomyomata)2 (0.9%) Unknown35 (17.2%)Ethnicity CaucasianNA197 (96.6%)208 (94.5%) Asian4 (1.9%)2 (0.9%) Middle Eastern1 (0.5%)0 (0.0%) South American1 (0.5%)0 (0.0%) Indigenous Australian0 (0.0%)4 (1.8%) Black African0 (0.0%)1 (0.5%) Pacific Islander0 (0.0%)1 (0.5%) Missing1 (0.5%)4 (1.8%)[^1]

The length of the CA repeat in the IGF1 promoter
------------------------------------------------

The length of the *IGF1* repeat (number of copies of the CA motif) ranged from 12 to 22 across all three cohorts. The mean numbers of copies of the CA motif were 19.06, 19.02 and 18.98 for the healthy control, breast cancer and endometrial cancer cohorts, respectively. The most common allele length seen was 19 CA repeats, which was observed in 67.9, 67.6 and 72.8% of alleles in the healthy controls, breast cancer patients and endometrial cancer patients, respectively ([Table 2](#tbl2){ref-type="table"}). The distribution of allele lengths when grouped against the most common allele length of 19 CA repeats is shown in [Table 2](#tbl2){ref-type="table"}. The most common genotype was the homozygote CA19/19, which was observed with a frequency of 59.5, 62.0 and 68.7% in the healthy control, breast cancer and endometrial cancer cohorts, respectively. Table 2Distribution of allele lengths for the *IGF1* STR in the healthy controls, breast cancer cohorts and endometrial cancer cohorts.**CA\<19CA=19CA\>19*n***Healthy controls58 (13.2%)299 (67.9%)83 (18.9%)440Breast cancer cohorts67 (15.2%)299 (67.6%)76 (17.2%)442Endometrial cancer cohorts61 (15.6%)284 (72.8%)45 (11.5%)390[^2]

The association of *IGF1* STR length with breast and endometrial cancer risk
----------------------------------------------------------------------------

As the distribution of STR lengths is slightly skewed, the Mann--Whitney rank-sum test was used to test for association between *IGF1* STR length and breast or endometrial cancer occurrence. The results tended towards an association when both allele lengths were analysed in relation to breast cancer risk (*P*=0.029) and for endometrial cancer risk (*P*=0.011; [Table 3](#tbl3){ref-type="table"}), although they did not pass our stringent Bonferroni-adjusted threshold for multiple testing (*α*=0.008). There was no association between the length of both alleles and cancer risk when considering age at diagnosis for breast cancer (hazard ratio (HR)=0.989 (95% confidence interval (CI)=0.901--1.086), *P*=0.824) or endometrial cancer (HR=0.952 (95% CI=0.863--1.052), *P*=0.335), nor when BMI was adjusted for in the endometrial cancer cohort (HR=0.951 (95% CI=0.854--1.060), *P*=0.366; [Table 3](#tbl3){ref-type="table"}). BMI data were not available for the breast cancer cohort. Table 3HR, 95% CI and *P* values for breast and endometrial cancer case--control analysis in relation to*IGF1* STR lengths.**CategoryStatistical testBreast cancer** (*n*=221)**Endometrial cancer** (*n*=195)HR (95% CI)*P* valueHR (95% CI)*P* valueBoth allele lengths with cancer riskMann--Whitney *U* testNA**0.029**NA**0.011**Both allele lengths with age at diagnosisCox proportional hazard regression0.989 (0.901--1.086)0.8240.952 (0.863--1.052)0.335Both allele lengths with age at diagnosis; BMI consideredCox proportional hazard regressionNANA0.951 (0.854--1.060)0.366Short allele length with cancer riskMann--Whitney *U* testNA0.184NA0.780Short allele length with age at diagnosisCox proportional hazard regression1.009 (0.884--1.150)0.8971.065 (0.908--1.249)0.442Short allele length with age at diagnosis; BMI consideredCox proportional hazard regressionNANA1.051 (0.886--1.248)0.567Long allele length with cancer riskMann--Whitney *U* testNA0.105NA**0.0012**Long allele length with age at diagnosisCox proportional hazard regression0.960 (0.821--1.122)0.608**0.794** (0.659--0.956)**0.015**Long allele length with age at diagnosis; BMI consideredCox proportional hazard regressionNANA**0.806** (0.659--0.986)**0.036**Categorical analysis (three groups; [Table 2](#tbl2){ref-type="table"})Pearson's *χ*^2^ testNA0.621NA**0.013**[^3]

When the allele lengths were categorised according to the most common allele length of 19 CA repeats, a sizeable decrease in the number of long alleles (CA \> 19) in the endometrial cancer cohort ([Table 2](#tbl2){ref-type="table"}) led to an association between this polymorphic CA repeat and the risk of developing endometrial cancer that tends towards significance (*P*=0.013; [Table 3](#tbl3){ref-type="table"}). This association was due to less long alleles observed (CA \>19; 11.5%; [Table 2](#tbl2){ref-type="table"}) than expected (15.4%) in the endometrial cancer cases compared with more long alleles (18.9%) than expected (15.4%) in the healthy controls (*P*=0.013; [Table 3](#tbl3){ref-type="table"}).

This association was verified when the STR allele lengths were considered separately. No association was seen when the short allele lengths were considered separately for both cancer types (for breast cancer, *P*=0.184; for endometrial cancer, *P*=0.780), nor when the long allele was considered for breast cancer risk (*P*=0.105; [Table 3](#tbl3){ref-type="table"}). However, a significant association was observed between the long alleles and the risk of developing endometrial cancer (*P*=0.0012; [Table 3](#tbl3){ref-type="table"}). In order to check that varied ethnicity between cohorts is not confounding this analysis, the 7 non-Caucasian endometrial cancer cases and 12 non-Caucasian healthy controls were removed from the case--control analysis (data not shown). This resulted in HRs that were unchanged from those presented in [Table 3](#tbl3){ref-type="table"}, and the above-mentioned *P* value (*P*=0.0012) for association between the long alleles and the risk of developing endometrial cancer remained significant (*P*=0.0015). The size of this association was moderated when age at diagnosis (*P*=0.015) and BMI (*P*=0.036) were considered, suggesting that these may be confounding factors in the association. For this reason, larger cohorts need to be analysed to confirm these associations.

Discussion
==========

When present in regulatory regions, polymorphic tandem repeats (TRs) such as the CA repeat in the promoter of the *IGF1* gene can have profound effects on gene expression and hence protein abundance and, therefore, impact on the risk and severity of disease ([@bib48]). However, TRs remain an under-explored source of genomic variation, largely due to their inability to be analysed on a large scale, with recent emphasis being on genome-wide association studies, which are unable to detect polymorphisms produced by variable TRs ([@bib49]). High-throughput techniques, such as next-generation sequencing, are not readily amenable to analysing TRs ([@bib50]) mainly due to problems with alignment and assembly of the regions containing stretches of TRs from short reads ([@bib51], [@bib52]). Other problems that occur when analysing TRs are due to inconsistencies in their definition, their heterogeneity and the fast evolution of some TR-containing regions ([@bib53]). Also, selecting appropriate statistical methods is problematic due to the multitude of allele lengths generated by polymorphic TRs, which can be treated as continuous numerical variables or grouped to form alternate variables to fit with standard bi-allelic genetic analysis ([@bib54]). Hence, these technical limitations make the analysis of TRs tedious and difficult to obtain large sample numbers.

Analysis of the dinucleotide repeat in the promoter of the *IGF1* gene in our healthy population and in breast and endometrial cancer patient samples confirmed its variability. There was no significant association seen between the length of this CA repeat and the risk of developing breast cancer, which is in agreement with the results of recent meta-analyses in mainly Caucasian populations, including one that involved nine studies with a total of 5641 cases and 10,471 controls ([@bib40]) and another that included seven studies with 3533 breast cancer cases and 7771 controls ([@bib18]). A meta-analysis conducted recently on the effect of this repeat on the risk of developing breast cancer (which included 11 studies of various ethnicity groups with a total of 7047 cases and 12,096 controls) reported a decreased risk of breast cancer in the Caucasian population associated with the CA 19/19 repeat genotype; however, the significance of the *P* values was borderline in this analysis, and the threshold had not been corrected for multiple testing ([@bib55]).

A significant association was observed between the long alleles for the CA repeat in the *IGF1* promoter and the risk of developing endometrial cancer in our study (*P*=0.0012), which was because the length of the long alleles is significantly shorter in the endometrial cancer cohort compared with the healthy controls. The direction of this association is in agreement with that seen for the same STR in the *IGF1* promoter in a previous breast cancer risk study, which found shorter alleles to be a risk factor ([@bib26]), as well as with an association between shorter alleles and an earlier age of onset for colorectal cancer ([@bib36], [@bib37], [@bib38]). There remains the possibility of ethnically distinct allele sizes confounding this type of analysis ([@bib56]). As it was recognised that these cohorts were not homogeneous, the analysis was repeated after removal of the results for the small number of non-Caucasian endometrial cancer and control samples, which resulted in unchanged hazard ratios and equivalent *P* values.

It may be that a particular length of this STR is required for optimal transcriptional activity and hence optimal expression of this gene. The presence of variable TRs in regulatory regions can affect gene expression ([@bib57]) due to alterations in DNA structure away from the usual double-helix B-DNA formation ([@bib58]). An unusual DNA structure, known as Z-DNA, is predicted to form when negative torsional strain occurs as a result of STRs with motif sequences composed of alternating purine-pyrimidine bases, such as the CA repeat which is commonly found in the human genome, especially in promoter regions ([@bib58]). This could affect transcription by blocking RNA polymerase activity, altering accessibility of transcription factor binding sites or altering binding of regulatory elements due to changed chromatin structure ([@bib58]). Hence, it is important to consider all allele lengths ([@bib18], [@bib26]), and not only whether the most common allele length (of 19 CA repeats) is present or absent as done in some previous studies ([@bib19], [@bib39], [@bib55]).

In summary, our results support the notion that there is no association between this polymorphic dinucleotide CA repeat in the *IGF1* promoter and the risk of developing breast cancer. However, the association of this STR with the risk of developing endometrial cancer is a new and interesting finding. Although further analyses of larger cohorts and those with varied ethnicity are required to confirm this association, it raises the possibility of this polymorphic STR being used as a biomarker for screening individuals at an increased risk of developing endometrial cancer in the future.
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[^1]: NA, not available; BMI, body mass index; UPSC, uterine papillary serous carcinoma; MMMT, malignant mixed Mullerian tumours.

[^2]: The actual number of allele lengths observed is shown with the percentage of total number of alleles enclosed by parentheses.

[^3]: Significant *P* values and associated HRs are highlighted in bold
